Systemic Lupus Erythematosus
Systemic lupus erythematosus (SLE), a systemic, connective tissue disease that can affect multiple organ systems, affects women, especially Asian and African women more commonly (Silpa-archa et al. 2016). Up to one-third of SLE patients experience some kind of ocular manifestation (Palejwala et al. 2012), keratoconjunctivitis sicca being the most common form, and retinal and choroidal involvement being most associated with visual impairment (Sivaraj et al. 2007; Palejwala et al. 2012). Although, the prevalence of SLE as a cause of uveitis was estimated to be 0.47% in a recent review of the literature (Gallagher et al. 2015), ocular involvement in SLE is important as it may correlate with systemic disease activity and precede other systemic symptoms.
- Dooley MA, Houssiau F, Aranow C, D’Cruz DP, Askanase A, Roth DA, Zhong ZJ, Cooper S, Freimuth WW, Ginzler EM, BLISS-52 and -76 Study Groups. Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE. Lupus. 2013;22(1):63–72. https://doi.org/10.1177/0961203312465781.CrossRefPubMedGoogle Scholar
- Navarra SV, Guzman RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, Li EK, Thomas M, Kim HY, Leon MG, Tanasescu C, Nasonov E, Lan JL, Pineda L, Zhong ZJ, Freimuth W, Petri MA, BLISS-52 Study Group. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9767):721–31. https://doi.org/10.1016/S0140-6736(10)61354-2.CrossRefPubMedPubMedCentralGoogle Scholar